BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 32741023)

  • 21. CIAPIN1 and ABCA13 are markers of poor survival in metastatic ovarian serous carcinoma.
    Nymoen DA; Holth A; Hetland Falkenthal TE; Tropé CG; Davidson B
    Mol Cancer; 2015 Feb; 14():44. PubMed ID: 25889687
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinicopathological prognostic parameters in patients with tubo-ovarian carcinoma effusions.
    Davidson B; Elstrand MB
    Cytopathology; 2022 Jul; 33(4):479-492. PubMed ID: 35398934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rab25 is overexpressed in Müllerian serous carcinoma compared to malignant mesothelioma.
    Brusegard K; Stavnes HT; Nymoen DA; Flatmark K; Trope CG; Davidson B
    Virchows Arch; 2012 Feb; 460(2):193-202. PubMed ID: 22249560
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Argonaute, Dicer, and Drosha are up-regulated along tumor progression in serous ovarian carcinoma.
    Vaksman O; Hetland TE; Trope' CG; Reich R; Davidson B
    Hum Pathol; 2012 Nov; 43(11):2062-9. PubMed ID: 22647351
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BUB1 mRNA is significantly co-expressed with AURKA and AURKB mRNA in advanced-stage ovarian serous carcinoma.
    Davidson B; Nymoen DA; Elgaaen BV; Staff AC; Tropé CG; Kærn J; Reich R; Falkenthal TE
    Virchows Arch; 2014 Jun; 464(6):701-7. PubMed ID: 24756216
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Global miRNA expression analysis of serous and clear cell ovarian carcinomas identifies differentially expressed miRNAs including miR-200c-3p as a prognostic marker.
    Vilming Elgaaen B; Olstad OK; Haug KB; Brusletto B; Sandvik L; Staff AC; Gautvik KM; Davidson B
    BMC Cancer; 2014 Feb; 14():80. PubMed ID: 24512620
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
    Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
    Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interleukin-8 and vascular endothelial growth factor mRNA and protein levels are down-regulated in ovarian carcinoma cells in serous effusions.
    Davidson B; Reich R; Kopolovic J; Berner A; Nesland JM; Kristensen GB; Tropé CG; Bryne M; Risberg B; van de Putte G; Goldberg I
    Clin Exp Metastasis; 2002; 19(2):135-44. PubMed ID: 11964077
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Aurora B expression in metastatic effusions from advanced-stage ovarian serous carcinoma is predictive of intrinsic chemotherapy resistance.
    Hetland TE; Nymoen DA; Holth A; Brusegard K; Flørenes VA; Kærn J; Tropé CG; Davidson B
    Hum Pathol; 2013 May; 44(5):777-85. PubMed ID: 23114921
    [TBL] [Abstract][Full Text] [Related]  

  • 30. AZGP1 and SPDEF mRNA expression differentiates breast carcinoma from ovarian serous carcinoma.
    Stavnes HT; Nymoen DA; Langerød A; Holth A; Børresen Dale AL; Davidson B
    Virchows Arch; 2013 Feb; 462(2):163-73. PubMed ID: 23242172
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expression levels of the nerve growth factor receptors TrkA and p75 in effusions and solid tumors of serous ovarian carcinoma patients.
    Davidson B; Lazarovici P; Ezersky A; Nesland JM; Berner A; Risberg B; Tropé CG; Kristensen GB; Goscinski M; van de Putte G; Reich R
    Clin Cancer Res; 2001 Nov; 7(11):3457-64. PubMed ID: 11705863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognostic impact of HER3 based on protein and mRNA expression in high-grade serous ovarian carcinoma.
    Unger U; Denkert C; Braicu I; Sehouli J; Dietel M; Loibl S; Darb-Esfahani S
    Virchows Arch; 2017 Feb; 470(2):143-151. PubMed ID: 27913862
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Snail, Slug, and Smad-interacting protein 1 as novel parameters of disease aggressiveness in metastatic ovarian and breast carcinoma.
    Elloul S; Elstrand MB; Nesland JM; Tropé CG; Kvalheim G; Goldberg I; Reich R; Davidson B
    Cancer; 2005 Apr; 103(8):1631-43. PubMed ID: 15742334
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ets-1 mRNA expression in effusions of serous ovarian carcinoma patients is a marker of poor outcome.
    Davidson B; Risberg B; Goldberg I; Nesland JM; Berner A; Tropé CG; Kristensen GB; Bryne M; Reich R
    Am J Surg Pathol; 2001 Dec; 25(12):1493-500. PubMed ID: 11717538
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells.
    Davidson B
    Hum Pathol; 2016 Dec; 58():123-127. PubMed ID: 27589896
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Calreticulin expression is reduced in high-grade ovarian serous carcinoma effusions compared with primary tumors and solid metastases.
    Vaksman O; Davidson B; Tropé C; Reich R
    Hum Pathol; 2013 Dec; 44(12):2677-83. PubMed ID: 24060004
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases.
    Hetland TE; Holth A; Kærn J; Flørenes VA; Tropé CG; Davidson B
    Virchows Arch; 2012 May; 460(5):505-13. PubMed ID: 22476403
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of EGFR, PD-L1, and the mismatch repair proteins before and following therapy in malignant serous effusions with metastatic high-grade serous tubo-ovarian carcinoma.
    Nikas IP; Park SY; Song MJ; Lee C; Ryu HS
    Diagn Cytopathol; 2024 Feb; 52(2):69-75. PubMed ID: 37937321
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HOXB8 expression in ovarian serous carcinoma effusions is associated with shorter survival.
    Stavnes HT; Holth A; Don T; Kærn J; Vaksman O; Reich R; Trope' CG; Davidson B
    Gynecol Oncol; 2013 May; 129(2):358-63. PubMed ID: 23438671
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ezrin Is Associated with Disease Progression in Ovarian Carcinoma.
    Horwitz V; Davidson B; Stern D; Tropé CG; Tavor Re'em T; Reich R
    PLoS One; 2016; 11(9):e0162502. PubMed ID: 27622508
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.